Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 22 December 2016 Biocartis submits 510(k) file with US FDA for Idylla™ platform Submission done in parallel with 510(k) submission of Janssen Idylla™ Respiratory (IFV-RSV) Panel Test by Janssen Diagnostics Non-regulated information 22 December 2016 Biocartis and Amgen sign a RAS Biomarker Testing Collaboration in Europe Inside information Regulated information 15 December 2016 CE-marking Idylla™ NRAS-BRAF Mutation Test completes offering of metastatic colorectal cancer tests for clinical use on Idylla™ platform Non-regulated information 14 December 2016 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 12 December 2016 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 7 December 2016 Biocartis launches second liquid biopsy assay Assay co-developed with Merck for detection of KRAS mutations, operating directly on 1 ml blood plasma Non-regulated information 28 November 2016 Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 21 November 2016 Disclosure of Outstanding Voting Securities Regulated information 17 November 2016 Thermo Fisher Scientific to Distribute Biocartis’ Idylla™ Automated Molecular Diagnostics Testing Platform in U.S. Inside information Regulated information 17 November 2016 Biocartis Q3 2016 Business Update Regulated information Pagination First page « First Previous page ‹‹ … Page 24 Page 25 Page 26 Page 27 Current page 28 Page 29 Page 30 Page 31 Page 32 Next page ›› Last page Last »